

# Asprosin, a Novel Therapeutic Candidate for Painful Neuropathy: An Experimental Study in Mice

**Sibel Ozcan**

Firat University School of Medicine

**Muhammed Mirac Kelestemur**

Firat University School of Medicine

**Munever Gizem Hekim**

Firat University School of Medicine

**Ozgur Bulmus**

Balikesir University Faculty of Medicine

**Ferah Bulut**

Firat University School of Medicine

**Batuhan Bilgin**

Firat University School of Medicine

**Sinan Canpolat**

Firat University School of Medicine

**Mete Ozcan** (✉ [mozcan@firat.edu.tr](mailto:mozcan@firat.edu.tr))

Firat University Medical School <https://orcid.org/0000-0002-5551-4880>

---

## Research Article

**Keywords:** Asprosin, neuropathic pain, hot plate test, cold plate tests, Von Frey test

**Posted Date:** November 18th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-1055710/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Naunyn-Schmiedeberg's Archives of Pharmacology on January 5th, 2022. See the published version at <https://doi.org/10.1007/s00210-021-02197-w>.

# Abstract

Neuropathic pain is primarily caused by nervous system lesions or dysfunction. Evidence strongly suggests that obesity, diabetes and cancer are common in chronic pain conditions, and pain complaints are common in these individuals. Recent studies indicate presence of a strong link between adipokines and neuropathic pain. However, the effects of asprosin, a novel adipokine, on neuropathic pain have not been studied in animal models

Mouse models were employed to investigate the antinociceptive effectiveness of asprosin in the treatment of three types of neuropathic pain, with metabolic (streptozocin/STZ), toxic (oxaliplatin/OXA), and traumatic (sciatic nerve ligation/CCI [chronic constriction nerve injury]) etiologies, respectively. Changes in nociceptive behaviors were assessed relative to controls using thermal (the hot plate and cold plate tests, at 50 °C and 4 °C respectively) and mechanical pain (Von Frey test) tests at baseline and 30, 60, 120 and 180 minutes after asprosin administration. Serum level of asprosin was quantified by ELISA.

In all three neuropathic pain models (STZ, OXA and CCI), asprosin administration significantly reduced both mechanical and thermal hypersensitivity, indicating that it exhibits a clear-cut antihypersensitivity effect in the analyzed neuropathic pain models. Asprosin levels were significantly lower in three types of neuropathic pain compare to controls ( $p < 0.05$ ).

The results yielded by the present study suggest that asprosin exhibits an analgesic effect in the neuropathic pain models and may have clinical utility in alleviating chronic pain associated with disease and injury originating from peripheral structures.

## Introduction

Neuropathic pain is a severe pathology of the nervous system that offers no adaptable benefit. The neuropathic pain has recently received much attention due to the alarming increases in the prevalence of obesity, diabetes and cancer (Yawn et al., 2009, Treede, 2018). In addition, further evidence also suggests people with obesity are more pain sensitive (Stone and Broderick, 2012){Stone, 2012 #172}. Although neuropathic pain etiology is not fully understood, available evidence points to an association with obesity, as excessive levels of adipose tissue hormones and adipokines affect neuropathic pain. Numerous adipokines may play an important role in pain sensitivity and transmission, and may thus be one of the possible targets in the treatment of pain (Pottie et al., 2006, Sharma, 2018).

When asprosin, a hormone released from white fat cells, reaches the liver, it causes rapid glucose release into the circulation. Asprosin is encoded by the fibrillin 1 (FBN1) gene and comprises of 140 amino acids, with a weight of about 30 kDa (Romere et al., 2016). Its levels may change in obesity, diabetes and metabolic syndrome associated with insulin resistance (Romere et al., 2016, Ugur and Aydin, 2019, Wang et al., 2019, Zhang et al., 2020). Asprosin dysfunction is caused by immunological or genetic factors, and results in a significant decrease in glucose and insulin concentrations. Administration of asprosin also increases blood glucose levels in healthy mice (Romere et al., 2016), but has no effects on diabetic mice

(Hekim et al., 2021). Prior investigations further indicate that plasma asprosin crosses the blood-brain barrier and activates orexigenic AMP-dependent-activated-related neuropeptide (AgRP) neurons in hypothalamus. This signaling results in inhibition of anorexigenic pre-opiomelanocortin (POMC) neurons in a GABA-dependent manner (Greenhill, 2016, Duerschmid et al., 2017, Beutler and Knight, 2018, Li et al., 2018, Ozcan et al., 2020). While activation of AgRP and POMC neurons have been shown to influence pain as well as appetite (Cerritelli et al., 2016, Alhadeff et al., 2018), it is not known whether asprosin levels change in mice models for painful neuropathy. There are the possible association between impaired glucose tolerance and neuropathy (Rajabally, 2011). In addition, the effects of glycogenic hormone asprosin on neuropathic pain that cause hyperalgesia in mice models are also unknown.

Given that animal models can mimic the changes in nociceptive behaviors in toxic, metabolic and traumatic neuropathic pain in humans, the aim of the present study was to investigate the effects of asprosin on changes in nociceptive behaviors in diabetes, chemotherapy and sciatic nerve injury-induced neuropathic pain using mouse models (Le Bars et al., 2001). Our further objective was to ascertain whether asprosin level changes in mouse models for painful neuropathy.

## Materials & Methods

### Animals

All experiments performed as a part of this study involved adult male Balb/C mice weighing 25 to 30 g and adhered fully to the guidelines of the ARRIVE (Animal in Research: In Vivo Experiments) as well as the principles of the International Association for the Study of Pain (IASP) Research and Ethics Committee (Zimmermann, 1983). This study was carried out with the approval of Firat University Animal Experiments Local Ethics Committee (dated 16.01.2019, protocol number 2019/06 with the decision number 2019/09). The animals were housed for one week before starting the experiments to acclimatize them and were maintained under standard laboratory conditions on a 12-hour light/dark cycle at a constant temperature ( $23 \pm 2$  °C) and humidity ( $60 \pm 5\%$ ) with food and water supplied ad libitum.

Behavioral tests were performed on all groups in a quiet room at the same time by the same researchers blind to the randomization, thus minimizing the influence of environmental factors and researcher effects. Tests and exercises were conducted between 9.00 am and 12.00 am and all treatments were delivered intraperitoneally (i.p) (Figure 1).

### Healthy Mice

Healthy animals were randomly divided into five subgroups: control, morphine group (50 mg/kg), asprosin (1 µg/kg), asprosin (10 µg/kg), and asprosin (30 µg/kg) (n=7, each group). We first evaluated the effectiveness of asprosin (1, 10 and 30 µg/kg, i.p.) and morphine (10 mg/kg) on nociceptive behavior in healthy animals, which were individually acclimatized to the environment and test setup, respectively. The effective dose of asprosin used in this study was calculated as  $\text{LogEC}_{50} = 0.9281$ .

## **Streptozotocin-induced diabetes model in mice**

The streptozotocin (STZ)-induced diabetic neuropathic pain group was randomly divided into three subgroups: STZ (diabetic control), STZ+asprosin (10 µg /kg), and STZ+gabapentin (50 mg/kg) (n=10, each group). Which were determined to be normoglycemic were administered STZ i.p. at a dose of 150 mg/kg. STZ was dissolved in 0.4 ml (0.1 M) Na<sup>+</sup> citrate buffer (pH 4.5). The control group was injected i.p. with the solvent sodium citrate buffer. Three days later, blood glucose was measured with manual glucometer (Optima, Taiwan) in all groups (all measurements were made between 9.00 and 10.00 am). Only mice with glucose levels above 250 mg/dL in blood taken from the tail vein were retained. From this group, mice that lost ≥10% of body weight before starting the experiment, exhibited decreased activity or hair erection were also excluded. Behavioral tests were conducted three weeks after STZ administration to mice.

## **Induction of neuropathy: Chronic constriction nerve injury**

The neuropathic pain group with sciatic nerve chronic constriction injury (CCI) was divided into three subgroups: CCI (sham control), CCI+asprosin (10 µg /kg), and CCI+gabapentin (50 mg/kg) (n=10, each group). Chronic construction of the sciatic nerve was performed using clamps as previously described (Salvat et al., 2018). First, mice were anesthetized with a ketamine/xylazine mixture (3 mL/kg body weight i.p.) and right sciatic nerve was exposed after dissection. Next, 2 mm PE-20 polyethylene tube (Harvard Apparatus, 59-8323, Les Ulis, France) was placed at around 5 mm distance from the trifurcation of the sciatic nerve, after which the wound was closed by suturing muscle (chromic catgut) and skin (3.0 silk). The sham groups were operated as described above, but without a polyethylene tube (cuff implantation). Animals with CCI were subjected to behavioral tests after 2 weeks of waiting for their wounds to heal.

## **Oxaliplatin-induced neuropathy**

The neuropathic pain group after oxaliplatin (OXA) use was also divided into three subgroups, denoted as OXA (control), OXA+asprosin (10 µg /kg), and OXA+gabapentin (50 mg/kg) ( n=10, each group). OXA (Sigma) was prepared at a concentration of 3 mg/mL in a 5% dextrose solution according to the weight of each animal and was administered i.p. at a dose of 3 mg/kg twice a week for 4.5 weeks. The control group was injected with 5% dextrose solution. After 2 weeks of 4.5 weeks of OXA drug administration, animals were subjected to behavioral tests.

## **Nociceptive test procedures**

Groups were determined by randomly selecting mice. Before commencing the behavioral tests, the animals assigned to all groups were numbered by marking their tails. Behavioral tests were performed on all groups in a quiet room between 9.00 am and 12.00 pm by the same researchers that were blind to randomization, thus minimizing the influence of environmental factors and researcher effects. Gabapentin (50 mg/kg, i.p.) was used as positive control.

**Hot plate test:** The *hot plate* test was performed by placing the animals on a warm floor within a clear plexiglass cylinder of 15 cm diameter and 22.5 cm height to prevent them from coming out. The hot plate analgesimeter table was set to  $50 \pm 0.5$  °C. Pain behavior was determined as the time (in seconds, with a 40 s cut-off) that lapsed from placing the animal on the floor to its visible reaction to pain (quickly pulling, licking or contracting its extremities). At the baseline, pain threshold values were determined before any injection was given to the mice (the time of injection was accepted as 0 minutes), and then measurements were performed 30, 60, 120, and 180 minutes after the injection.

**Cold plate test:** Cold hyperalgesia was evaluated using a *cold plate* at the optimum temperature of  $5 \pm 0.2$  °C. The sum of paw lifts and jumps during the 5-minute measurement interval (while excluding movement-related behaviors and coordinated movements of all four extremities) was considered a response to cold hyperalgesia. As with the *cold plate* test, the time of injection was accepted as 0 minutes, and further measurements were performed at 30, 60, 120, and 180 minutes after injection.

**Von Frey test:** Mechanical allodynia was assessed using von Frey filaments as previously described (Yalcin et al., 2014). Prior to testing, animals were acclimated to the environment and the test setup for 10 days. On the day of the test, animals were kept in the boxes for 15 minutes without any treatment, after which each von Frey filament was applied 5 times to the plantar surface of the right hind paw until it bent. The filament that produced the same response in at least three instances was defined as the result. These measurements were performed at baseline (i.e., before the mice were given any injections) and the time of injection was accepted as 0 minutes. The test was repeated one hour after injection. This procedure was applied to all groups.

### **Motor activity**

Rotarod test was used to determine motor coordination. Prior to testing, mice were acclimated to the environment and the test protocol by placing them on the fixed bar for 5 minutes for two consecutive days and then on the rotating bar while increasing its speed from 4 rpm to 40 rpm. Following the acclimation period, mice were placed on accelerating rotating rods to determine the effect of asprosin on motor activity and the time taken for the animals to fall off the rod was recorded (cut-off time = 300 s). As with other tests, the baseline measurements were performed before the mice were given any injections and the time of injection was accepted as 0 minutes. The test was repeated one hour after the injection, as this interval corresponds to the highest pain threshold. This procedure was applied to all groups.

### **Asprosin measurements**

Once all experimental protocols were completed, the animals were decapitated between 9.00 and 10.00 am and the blood serum were stored at -80 °C until required for analysis, which was performed using the mouse asprosin ELISA Kit (USCN catalog number: SEA332Mu) following the manufacturer's protocol. The amount of asprosin antigen in the serum was determined using a microplate coated with the asprosin antibody included in the kit. The color change that occurs at the end of the experiment indicates the presence of antigen and the measuring range of the kit spans from 78 to 5000 pg/mL, while its

sensitivity is  $\leq 32$  pg/mL, with the inter-assay and intra-assay %CV (coefficient of variation) values of  $\approx 12\%$  and  $\approx 10\%$ , respectively. The experimental protocol included in the ELISA kit was used to determine the serum asprosin level.

## **Drugs**

Gabapentin, STZ and OXA were purchased from Sigma. Gabapentin was prepared by dissolving in saline, while the recombinant asprosin (Elabscience Company, U.S.A.) was dissolved in phosphate buffered saline (PBS). All drugs were freshly prepared on the day of the experiment.

## **Statistical analyses**

SPSS Statistics 22.0 for Windows software package was used for all statistical analyses. Conformity to normal distribution was evaluated via the Shapiro Wilk test and oneway analysis of variance was performed to compare the values of quantitative variables between groups when there were three or more groups. When a significant difference was identified, multiple comparisons were conducted using Dunnet's test and Tukey test, with  $p < 0.05$  indicating statistical significance.

# **Results**

## **Effects of asprosin administration on pain behavior in healthy mice**

The effects of asprosin on thermal and mechanical hyperalgesia were evaluated using hot plate, cold plate and von Frey tests. We first tested effects of asprosin in healthy mice at different times (30, 60, 120 and 180 minutes) after injection. Asprosin (1  $\mu\text{g}/\text{kg}$ , 10  $\mu\text{g}/\text{kg}$ , and 30  $\mu\text{g}/\text{kg}$  i.p.) increased pain threshold compared to control group in healthy mice. Moreover, the antinociceptive effect caused by asprosin was similar to morphine (10 mg/kg), (Figure 2).

## **Effects of asprosin administration on pain behavior in diabetic mice**

There were significant decreases in nociceptive behavior latencies in diabetic mice compared with the healthy animals. Asprosin (10  $\mu\text{g}/\text{kg}$ ) treatment was significantly decreased mechanical and thermal hypersensitivity in diabetic animals. Gabapentin (50 mg/kg) caused significant increases in pain threshold compared with the vehicle group (10mg/kg) in diabetic mice. This effect of gabapentin was similar to asprosin treatment group in diabetic mice (Figure 3).

## **Effects of asprosin administration on neuropathic pain behavior after oxaliplatin use in mice**

The OXA-administered mice developed a significant hyperalgesic activity. Asprosin (10  $\mu\text{g}/\text{kg}$ ) treatment caused significant increases in pain threshold compared with the vehicle group (10mg/kg) in OXA-administered mice. Moreover, the antinociceptive effect caused by asprosin was found to be similar to gabapentin (50 mg/kg) in OXA-administered animals (Figure 4).

## **Effects of asprosin administration on neuropathic pain behavior after sciatic nerve injury in mice**

There were significantly different in the response time (or in the von Frey test results) between CCI and healthy animals. Asprosin (10 µg/kg) treatment was significantly decreased mechanical and thermal hypersensitivity in CCI animals. In addition, the antinociceptive effect caused by asprosin was found to be similar to gabapentin (50 mg/kg) in CCI animals (Figure 5).

### **Effect of asprosin administration on motor activity**

Rotarod test was used to evaluate the motor activity in mice. There were no effects asprosin treatment on motor coordination in neuropathic pain induced animals. However, CCI caused to significantly decreases in motor activity in mice according to healthy, diabetic and OXA-administered mice ( $p < 0.05$ ), (Figure 6).

### **Asprosin levels in healthy mice and those experiencing induced neuropathic pain**

Asprosin level in healthy mice was measured at  $54.5 \pm 8.9$  ng/mL. In order to determine whether asprosin levels change in neuropathic pain conditions, the same measurements were performed in toxic (oxaliplatin), metabolic (STZ), and traumatic (sciatic nerve construction injury) neuropathic pain groups. The findings revealed that asprosin level decreased in animals with neuropathic pain, as  $30.5 \pm 7.1$  ng/mL was obtained for animals with type 1 diabetes,  $23.1 \pm 7.3$  ng/mL for animals with neuropathy after OXA use, and  $22.0 \pm 6.9$  ng/mL for animals with neuropathy after CCI (Figure 7).

## **Discussion**

The findings yielded by the present study indicate that asprosin administration significantly reduced mechanical and thermal hypersensitivity in mouse models for different painful neuropathies (toxic, metabolic and traumatic). Moreover, asprosin levels in the neuropathic pain-induced group were significantly lower than in healthy mice.

Hunger and pain are two competing signals that individuals must respond to for their survival. Yet, the neural processes that prioritize these conflicting survival needs are poorly understood (Alhadeff et al., 2018). Findings yielded by extant studies indicate that some orexinergic/anorexigenic peptides influence nociceptive behaviors. Leptin, ghrelin and orexin were demonstrated to inhibit the development of neuropathic pain in rodents (Vergnano et al., 2008, Chiou et al., 2010, Guneli et al., 2010, Li et al., 2013). However, kisspeptin has been shown to exert lowers pain threshold and enhances nocifensive behavior in mice (Elhabazi et al., 2013, Kelestimur et al., 2021). Many studies have been published regarding the possible association between impaired glucose tolerance and neuropathy, but the actual responsibility of impaired glucose tolerance as cause of neuropathy remains still uncertain (Rajabally, 2011). In the present investigation based on a mouse model, we focused on asprosin (a glycopeptide), and found that it induces changes in nociceptive behaviors in neuropathic pain. Our findings are consistent with those yielded by previous research, indicating that pain may be affected not just by appetite hormones, but also by the projections of orexinergic nerves and distribution of orexinergic receptors in the body.

It has been determined that the spinal cord carries primary afferent nociceptive and thermoreceptive information from orexinergic neurons and sends projections to the superficial dorsal horn (lamina I and II) (van den Pol, 1999, Berrendero et al., 2018). Studies in rat superficial dorsal horn cells similarly show that anorexigenic/orexinergic peptides play a role in arousal, nociception, pain and temperature sensations (Grudt and Perl, 2002). The activity of orexinergic AgRP neurons in the hypothalamus has been shown to inhibit both thermal acute pain and inflammatory pain (Alhadeff et al., 2018). Available findings further indicate that activation of anorexigenic POMC neurons in the brain stem produces opioidergic analgesia (Cerritelli et al., 2016). As asprosin increases appetite via AgRP and POMC neurons, changes in nociceptive behaviors following asprosin administration in this study may be attributed to the activation of AgRP and POMC neurons. The association between asprosin and orexinergic/anorexigenic neurons (including neuropathic pain processes) should thus be examined in more detail to confirm or refute this assertion. Although there is a positive association with obesity and pain threshold, the mechanisms underpinning this link are not fully understood (McCarthy et al., 2009, Eslick, 2012, Stone and Broderick, 2012). According to the prior studies in this field, asprosin level increases in obesity, type 2 diabetes and metabolic syndrome. Several authors are of view that asprosin level increases in parallel with the increase in adipose tissue in obese and diabetic individuals and animals (Romere et al., 2016, Ugur and Aydin, 2019, Wang et al., 2019, Zhang et al., 2020). However, Long et al. observed significantly lower asprosin levels in obese children. At the same time studies demonstrated that there are no association between plasma asprosin concentration and body mass in polycystic ovary syndrome (PCOS) and elderly women with metabolic disorders (Chang et al., 2019, Long et al., 2019, Wiecek et al., 2019). Another study reported by our study group indicate that serum asprosin levels in obese male rats are similar with female rats (Ozcan et al., 2020). The excess adipose tissue in obesity has been linked to the risk of developing insulin resistance and metabolic syndrome. In individuals with type 1 diabetes that develop hypoglycemia, lower asprosin response is associated with insulin resistance. The patients with type 1 diabetes may have a blunted response to asprosin (Groener et al., 2019). The degree of diabetes control may also be an important factor influencing asprosin levels (Chen et al., 2005, Paisley and Serpell, 2016, Callaghan et al., 2020). In the current study, the decrease in asprosin levels in the neuropathic pain-induced groups may cause painful neuropathy. On the other hand, it is possible that asprosin administration may reduce hypersensitivity in painful neuropathy. The duration and severity of diabetes may play an important role in pain formation, as this condition can cause hyperalgesia and allodynia, as well as loss of sensation (hypoalgesia) (Chen et al., 2005, Paisley and Serpell, 2016).

Many studies have been published regarding the possible association between impaired glucose tolerance and neuropathy, but the actual responsibility of impaired glucose tolerance as cause of neuropathy remains still uncertain.

In conclusion, these results clearly demonstrate, for the first time, that asprosin exerts an antinociceptive effect on neuropathic pain of different etiologies in mice. We also provide critical preliminary evidence suggesting that asprosin treatment and serum asprosin levels may be a novel therapeutic candidate for painful neuropathy.

# Declarations

## Data Availability Statement

The data presented in this study are available on request from the corresponding author.

## Code availability

Not applicable

## Affiliations

**Department of Anaesthesiology and Reanimation, Faculty of Medicine, Firat University, Elazig, Turkey.**  
Sibel Ozcan

**Department of Biophysics, Faculty of Medicine, Firat University, Elazig, Turkey.** Muhammed Mirac Kelestemur, Ferah Bulut, Batuhan Bilgin & Mete Ozcan

**Department of Physiology, Faculty of Medicine, Firat University, Elazig, Turkey.** Munevver Gizem Hekim & Sinan Canpolat

**Department of Physiology, Faculty of Medicine, Balikesir University, Balikesir, Turkey.** Ozgur Bulmus

## Contributions

S.O., M.O.; designed the study, contributed to the analysis of data and preparation of manuscript. S.C., O.O.; designed the study and contributed to experimental study. M.M.K., M.G.H., F.B., B.B: The experiments perform. S.O., M.O.; Manuscript preparation and critical revision. All authors read and approved the manuscript. The authors declare that all data were generated in-house and that no paper mill was used.

## Corresponding author

Correspondence to Mete Ozcan

Ethics declarations

## Ethics/animal welfare approval

All experiments adhered fully to the guidelines of the ARRIVE (Animal in Research: In Vivo Experiments) as well as the principles of the International Association for the Study of Pain (IASP) Research and Ethics Committee. This study was carried out with the approval of Firat University Animal Experiments Local Ethics Committee (dated 16.01.2019, protocol number 2019/06 with the decision number 2019/09).

## Consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Conflict of interest

The authors declare that they have no competing interests.

## Acknowledgements

This study was sponsored by Turkish Scientific Technical Research Organization (TUBITAK Project No: 119S138).

## References

1. Alhadeff AL, Su Z, Hernandez E, Klima ML, Phillips SZ, Holland RA, Guo C, Hantman AW, De Jonghe BC, Betley JN (2018) A Neural Circuit for the Suppression of Pain by a Competing Need State. *Cell* 173: 140-152.e115
2. Berrendero F, Flores Á, Robledo P (2018) When orexins meet cannabinoids: Bidirectional functional interactions. *Biochem Pharmacol* 157: 43-50
3. Beutler LR, Knight ZA (2018) A spotlight on appetite. *Neuron* 97: 739-741
4. Callaghan BC, Gallagher G, Fridman V, Feldman EL (2020) Diabetic neuropathy: what does the future hold? *Diabetologia* 63: 891-897
5. Cerritelli S, Hirschberg S, Hill R, Balthasar N, Pickering AE (2016) Activation of Brainstem Pro-opiomelanocortin Neurons Produces Opioidergic Analgesia, Bradycardia and Bradypnoea. *PloS one* 11: e0153187
6. Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK (2019) The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. *Sci Rep* 9: 6447
7. Chen YS, Chung SS, Chung SK (2005) Noninvasive monitoring of diabetes-induced cutaneous nerve fiber loss and hypoalgesia in thy1-YFP transgenic mice. *Diabetes* 54: 3112-3118
8. Chiou LC, Lee HJ, Ho YC, Chen SP, Liao YY, Ma CH, Fan PC, Fuh JL, Wang SJ (2010) Orexins/hypocretins: pain regulation and cellular actions. *Curr Pharm Des* 16: 3089-3100
9. Duerschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M (2017) Asprosin is a centrally acting orexigenic hormone. *Nature medicine* 23: 1444-1453
10. Elhabazi K, Humbert JP, Bertin I, Schmitt M, Bihel F, Bourguignon JJ, Bucher B, Becker JA, Sorg T, Meziane H, Petit-Demoulière B, Ilien B, Simonin F (2013) Endogenous mammalian RF-amide

- peptides, including PrRP, kisspeptin and 26RFa, modulate nociception and morphine analgesia via NPFF receptors. *Neuropharmacology* 75: 164-171
11. Eslick GD (2012) Gastrointestinal symptoms and obesity: a meta-analysis. *Obes Rev* 13: 469-479
  12. Greenhill C (2016) Asprosin—new hormone involved in hepatic glucose release. *Nature Reviews Endocrinology* 12: 312-312
  13. Groener JB, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T, Nawroth PP, Kopf S (2019) Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. *PLoS One* 14: e0222771
  14. Grudt TJ, Perl ER (2002) Correlations between neuronal morphology and electrophysiological features in the rodent superficial dorsal horn. *J Physiol* 540: 189-207
  15. Guneli E, Onal A, Ates M, Bagriyanik HA, Resmi H, Orhan CE, Kolatan HE, Gumustekin M (2010) Effects of repeated administered ghrelin on chronic constriction injury of the sciatic nerve in rats. *Neurosci Lett* 479: 226-230
  16. Hekim MG, Kelestemur MM, Bulmus FG, Bilgin B, Bulut F, Gokdere E, Ozdede MR, Kelestimur H, Canpolat S, Ozcan M (2021) Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. *Arch Physiol Biochem*: 1-7
  17. Kelestimur H, Bulut F, Canpolat S, Ozcan M, Ayar A (2021) Kisspeptin leads to calcium signaling in cultured rat dorsal root ganglion neurons. *Gen Physiol Biophys* 40: 155-160
  18. Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. *Pharmacol Rev* 53: 597-652
  19. Li X, Kang L, Li G, Zeng H, Zhang L, Ling X, Dong H, Liang S, Chen H (2013) Intrathecal leptin inhibits expression of the P2X2/3 receptors and alleviates neuropathic pain induced by chronic constriction sciatic nerve injury. *Mol Pain* 9: 65
  20. Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, Wang X, Qu H, Guo S, Long M, Zheng H (2018) Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. *Mediators Inflamm* 2018: 7375294
  21. Long W, Xie X, Du C, Zhao Y, Zhang C, Zhan D, Li Z, Ning Q, Luo X (2019) Decreased Circulating Levels of Asprosin in Obese Children. *Horm Res Paediatr* 91: 271-277
  22. McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB (2009) Chronic pain and obesity in elderly people: results from the Einstein aging study. *J Am Geriatr Soc* 57: 115-119
  23. Ozcan S, Ulker N, Bulmus O, Yardimci A, Ozcan M, Canpolat S (2020) The modulatory effects of irisin on asprosin, leptin, glucose levels and lipid profile in healthy and obese male and female rats. *Archives of physiology and biochemistry*: 1-8
  24. Paisley P, Serpell M (2016) Tailor treatment to the patient with neuropathic pain. *Practitioner* 260: 11-15
  25. Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F (2006) Obesity and osteoarthritis: more complex than predicted! *BMJ Publishing Group Ltd*

26. Rajabally Y (2011) Neuropathy and impaired glucose tolerance: an updated review of the evidence. *Acta neurologica scandinavica* 124: 1-8
27. Romere C, Duerschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR (2016) Asprosin, a Fasting-Induced Glucogenic Protein Hormone. *Cell* 165: 566-579
28. Salvat E, Yalcin I, Muller A, Barrot M (2018) A comparison of early and late treatments on allodynia and its chronification in experimental neuropathic pain. *Mol Pain* 14: 1744806917749683
29. Sharma A (2018) The role of adipokines in intervertebral disc degeneration. *Medical Sciences* 6: 34
30. Stone AA, Broderick JE (2012) Obesity and pain are associated in the United States. *Obesity (Silver Spring)* 20: 1491-1495
31. Treede R-D (2018) The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes. *Pain reports* 3
32. Ugur K, Aydin S (2019) Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. *Int J Endocrinol* 2019: 2521096
33. van den Pol AN (1999) Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. *J Neurosci* 19: 3171-3182
34. Vergnano AM, Ferrini F, Salio C, Lossi L, Baratta M, Merighi A (2008) The gastrointestinal hormone ghrelin modulates inhibitory neurotransmission in deep laminae of mouse spinal cord dorsal horn. *Endocrinology* 149: 2306-2312
35. Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC, Wen MS, Yeh TS (2019) Serum asprosin levels and bariatric surgery outcomes in obese adults. *Int J Obes (Lond)* 43: 1019-1025
36. Wiecek M, Szymura J, Sproull J, Szygula Z (2019) Decreased Blood Asprosin in Hyperglycemic Menopausal Women as a Result of Whole-Body Cryotherapy Regardless of Metabolic Syndrome. *J Clin Med* 8
37. Yalcin I, Megat S, Barthas F, Waltisperger E, Kremer M, Salvat E, Barrot M (2014) The sciatic nerve cuffing model of neuropathic pain in mice. *Journal of visualized experiments: JoVE*
38. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ, 3rd (2009) The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. *Pain Med* 10: 586-593
39. Zhang H, Hu W, Zhang G (2020) Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. *Int Urol Nephrol* 52: 1517-1522
40. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 16: 109-110

## Figures




Fig. 1.

Figure 1

Flowchart of experimental design




Fig. 2.

## Figure 2

Effect of asprosin (1, 10 and 30 $\mu$ g/kg, ip) on pain threshold in healthy mice. Mean $\pm$ SD values of mouse response to thermal and mechanical stimulus in healthy mice. Asprosin administered groups were compared with the control group using Dunnet's test  $p < 0.05$ , \*\* $p < 0.01$ ,  $p < 0.001$ . \* $p < 0.05$ . A) The mean $\pm$ SD values of the time-dependent response of healthy mice with the hot plate test, B) cold plate test and C) Von Frey test.




Fig.3.

### Figure 3

Effect of asprosin (10µg/kg, ip) and gabapentin (50mg/kg, ip) on pain threshold in diabetic mice. Asprosin and gabapentin administered groups were compared with the control group using Dunnet's test \*p<0.05, \*\*p<0.01, p<0.001. A)The mean±SD values of the time-dependent response of diabetic mice with the hot-plate test, B) cold plate test and C) Von Frey test.




Fig.4.

### Figure 4

The effect of asprosin (10µg/kg, ip) and gabapentin (50mg/kg, ip) on neuropathic pain behavior after oxaliplatin use in mice. Asprosin and gabapentin administered groups were compared with the control group using Dunnett's test \*p<0.05, \*\*p<0.01, p<0.001. A) The mean±SD values of the time-dependent response of diabetic mice with the hot-plate test, B) cold plate test and C) Von Frey test.




Fig.5.

### Figure 5

Effect of asprosin (10µg/kg, ip) and gabapentin (50mg/kg, ip) on neuropathic pain behavior after sciatic nerve construction injury in mice. Asprosin and gabapentin administered groups were compared with the control group using Dunnet's test \*p<0.05, \*\*p<0.01, p<0.001. A)The mean±SD values of the time-dependent response of diabetic mice with the hot-plate test, B) cold plate test and C) Von Frey test.





Fig.6.

## Figure 6

Mean±SD values of the response to falling from a spinning rod in mice undergoing the rotarod test. Comparisons were made using the Tukey test \* $p < 0.05$ , \*\* $p < 0.01$ ,  $p < 0.001$ . A) Evaluation of motor activities of mice after administration of asprosin at doses of 1, 10, 30  $\mu\text{g}/\text{kg}$  in healthy animals B) Evaluation of motor activities of diabetic mice after administration of asprosin (10  $\mu\text{g}/\text{kg}$ ) and gabapentin (50  $\text{mg}/\text{kg}$ ) C) Evaluation of motor activities of mice with neuropathy after oxaliplatin administration as a result of administration of asprosin (10  $\mu\text{g}/\text{kg}$ ) and gabapentin (50  $\text{mg}/\text{kg}$ ) D) Evaluation of the motor activities of mice with sciatic nerve chronic constriction injury with asprosin (10  $\mu\text{g}/\text{kg}$ ) and gabapentin (50  $\text{mg}/\text{kg}$ )



**Fig.7.**

### Figure 7

Asprosin levels in different models of neuropathic pain with animals (n=7 for each group). Comparisons between groups were made using the Tukey test. When animals with neuropathic pain were compared with healthy animals, \*P<0.01, \*\*P<0.001;DIN: Diabet Incuded Neuropathy, CCIN: Chronic Constriction Incuded Neuropathy, OIN: Oxaliplatin Incuded Neuropathy